Group

Age-Related Macular Degeneration (AMD) carries a substantial economic burden, impacting not only the individual patient but also the broader healthcare system and economy. The cost of AMD is multifaceted, encompassing direct medical costs from treatments, surgeries, and clinical visits, as well as indirect costs associated with vision loss, such as a loss of productivity, independence, and an increased risk of falls and depression. The market value of AMD treatments is therefore a reflection of this significant economic challenge. Anti-VEGF therapies, for example, are highly effective but also very expensive, with a single injection costing thousands of dollars. While this represents a high cost per dose, the total market value is a testament to the clinical necessity and efficacy of these drugs. The development of new, longer-lasting therapies aims to reduce the overall treatment burden and cost by decreasing the frequency of injections. Furthermore, the economic opportunity for dry AMD is immense, given the large patient population and the current lack of effective treatment. The first therapies to market for geographic atrophy are priced high, reflecting their innovative nature and the long-standing unmet need. For healthcare systems and insurers, the challenge lies in balancing the high cost of these innovative drugs with their proven clinical benefits and potential to reduce other associated healthcare costs. For a detailed breakdown of the economic landscape and market valuation, you can consult the in-depth Age-Related Macular Degeneration Market report.